

ABSTRACT OF THE DISCLOSURE

The present invention relates to tricyclic quinoxaline  
5 compounds and physiologically acceptable salts and prodrugs  
thereof which modulate the activity of protein tyrosine kinases  
and therefore should be useful in the prevention and treatment of  
protein tyrosine kinase related cellular disorders such as  
cancer.

10